Release date: 2024-07-30 14:19:37 Article From: Lucius Laos Recommended: 104
Anamorelin is a medication utilized in the treatment of specific ailments, and like all medications, Anamorelin may potentially elicit some adverse effects. Patients should be well informed of these potential side effects before commencing treatment and should use the drug under the guidance of a physician.
According to the label, common side effects of Anamorelin primarily include the following, requiring patients to closely monitor their own reactions and seek prompt medical attention if any discomfort arises.
Some patients may experience conduction system inhibition after using Anamorelin, potentially resulting in irregular heartbeats or decreased heart rate. It is recommended that patients undergo regular electrocardiogram examinations during the course of treatment.
Anamorelin may impact a patient's blood glucose levels, leading to the occurrence of hyperglycemia and potentially exacerbating existing symptoms of diabetes. Diabetic patients should exercise extra caution when using this medication, closely monitoring changes in blood glucose levels.
Anamorelin may also induce certain damage to the liver, causing abnormalities in liver function. Patients undergoing Anamorelin treatment should undergo regular liver function tests to promptly detect and address any potential issues.
Apart from the aforementioned common side effects, Anamorelin may also trigger some less common side effects such as difficulty breathing, pleural effusion, nausea, diarrhea, abdominal pain, decreased muscle strength, and muscle spasms. Despite the rarity of these side effects, patients should remain vigilant and seek immediate medical attention upon the onset of related symptoms.
Prior to using Anamorelin, patients should take note of the following contraindications:
Patients with conditions such as complete atrioventricular block should refrain from using Anamorelin, as the medication exerts a sodium channel inhibitory effect that may exacerbate symptoms.
Patients currently taking medications such as clarithromycin, itraconazole, voriconazole, ritonavir-containing preparations, cobicistat-containing preparations, or enzalutamide, which may interact with Anamorelin, should avoid concurrent use to prevent decreased drug efficacy or increased risk of side effects.
Due to the liver's crucial role in the metabolism and excretion of Anamorelin in the body, impaired liver function may lead to drug accumulation, elevated blood drug concentrations, and increased risk of side effects. Patients with moderate to severe hepatic impairment (Child-Pugh class B and C) should exercise caution or avoid the use of this medication.
[Warm tips] While Anamorelin serves in treating ailments, it may also present certain side effects and contraindications. Patients should be thoroughly informed of potential risks and precautions when using this medication and should seek advice from a medical professional if any concerns or discomfort arise.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: